Comparative Pharmacology
Head-to-head clinical analysis: INVAGESIC versus ROXIPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVAGESIC versus ROXIPRIN.
INVAGESIC vs ROXIPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
2.5 hours (prolonged to 4-6 hours in hepatic impairment; no significant change in renal impairment)
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Renal (70% as unchanged drug, 20% as glucuronide conjugate); biliary/fecal (10%)
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination